Health Care

IDEXX Laboratories’ surge in late‑November trading highlights its leading position in point‑of‑care veterinary diagnostics, backed by a global lab network and strong investor confidence.

Verrica Pharmaceuticals, a clinical‑stage dermatology firm, is developing innovative treatments for skin diseases like molluscum contagiosum, navigating market volatility while pursuing breakthrough therapies.

Jiangsu Hengrui’s new CFDA approvals for six oncology and autoimmune drugs boost its pipeline depth and investor confidence, positioning the firm for Phase‑III success and higher earnings.

Explore Clover Health Investments Corp’s Medicare Advantage strategy, market outlook, and recent stock performance for investors seeking growth in senior health care.

How aTyr Pharma’s legal storm and short‑seller pressure threaten its protein‑drug pipeline—and what investors should watch for next.

PACs Group hits a 52‑week high after insider buying, driving confidence in its post‑acute care expansion and future growth prospects.

Medios AG delivers patient‑specific pharma solutions, boosting care quality while showing solid market performance and growth potential.

VYNE Therapeutics: A biotech on the brink of breakthrough treatments for chronic itching and coughing, yet grappling with steep stock volatility and near‑zero profitability.

Vaxart’s oral flu vaccine could revolutionize flu prevention, yet the biotech’s steep financial struggles and regulatory hurdles keep its future uncertain.

Exelixis Inc. gains institutional backing and rides a projected rise in rhabdomyosarcoma market, with its Cabozantinib partnership poised to boost growth.